Yvonne M H Versleijen-Jonkers (Anke E M van Erp)

Years Active: 2018-2020
Publications (10 Years): 3

Radboudumc

Radboudumc (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Radboudumc Jan 01 2019

Netherlands

Scientific Researcher/PostDoc :: Medical Oncology

Radboudumc - Dec 31 2018

Netherlands

PhD Candidate :: Medical Oncology

Karolinska Institutet

Sweden

Master student :: Microbiology, Tumor and Cell Biology

Radboudumc

Netherlands

Master student :: Internal Medicine

Radboud Universiteit Nijmegen Radboud Institute for Molecular Life Sciences

Netherlands

Bachelor student :: Rheumatology Research and Advanced Therapeutics

Education History

Radboudumc

Netherlands

MSC

Radboudumc

Netherlands

BSC

Publications

Anke E M van Erp, Laurens van Houdt, Melissa H S Hillebrandt-Roeffen, Niek F H N van Bree, Uta E Flucke, Thomas Mentzel, Janet Shipley, Ingrid M E Desar, Emmy D G Fleuren, Yvonne M H Versleijen-Jonkers, Winette T A van der Graaf
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. Journal of cancer research and clinical oncology 146 (7) (2020)
Yvonne M H Versleijen-Jonkers, Yvonne M H Versleijen-Jonkers, Winette T A van der Graaf, Emmy D G Fleuren
Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma. Molecular cancer therapeutics 17 (7) (2019)
Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen, Laurens van Houdt, Emmy D G Fleuren, Winette T A van der Graaf, Yvonne M H Versleijen-Jonkers
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib. Targeted oncology 12 (6) (2018)

Yvonne M H Versleijen-Jonkers.css-eqlu8i{font-size:small;padding-left:4px;} (Anke E M van Erp)